IMM-003

IMM-003 is a preclinical therapeutic candidate being developed by RapaFusyn Pharmaceuticals for the treatment of immunological and inflammatory diseases. It is part of the company's RapaGlues™ platform, which leverages rapamycin-based macrocycles to function as molecular glues. These molecules are designed to induce the proximity of two proteins, leading to either the degradation of a disease-causing protein (molecular glue degraders) or the modulation of its activity (non-degrading molecular glues). As of early 2024, IMM-003 is in the hit identification stage, and its specific molecular target has not been publicly disclosed.